- 1 The Impact of Fontan Circulatory Failure on Heart Transplant Survival: A 20 Center
- 2 Retrospective Cohort Study
- 3
- 4 Kurt R Schumacher¹, David N Rosenthal², Adriana Batazzi¹, Sunkyung Yu¹, Garrett
- 5 Reichle¹, Maria Bano³, Shriprasad R Deshpande⁴, Matthew O'Connor⁵, Humera
- 6 Ahmed⁵, Sharon Chen², Lydia K. Wright⁷, Steven J Kindel⁸, Anna Joong⁹, Michelle
- 7 Ploutz⁶, Brian Feingold¹⁰, Justin Godown¹¹, Chad Y Mao¹², Angela Lorts¹³, Kathleen E.
- 8 Simpson¹⁴, Aecha Ybarra¹⁵, Marc E Richmond¹⁶, Shahnawaz Amdani¹⁷, Jennifer
- 9 Conway¹⁸, Elizabeth D Blume¹⁹, Melissa K Cousino¹
- 10 1. Congenital Heart Center, Department of Pediatrics, University of Michigan Medical
- 11 School, Ann Arbor, MI
- 12 2. Department of Pediatrics, Stanford University, Palo Alto, CA
- 13 3. Department of Pediatrics, Division of Cardiology, Children's Health, UT Southwestern,
- 14 Dallas, TX
- 15 4. Pediatric Cardiology, Children's National Hospital, George Washington University,
- 16 Washington, District of Columbia
- 17 5. The Children's Hospital of Philadelphia, Philadelphia, PA
- 18 6. Department of Pediatrics, University of Utah, Salt Lake City, UT
- 19 7. Nationwide Children's Hospital, Columbus, OH
- 20 8. Children's Wisconsin Herma Heart Institute, Department of Pediatrics, Medical
- 21 College of Wisconsin, Milwaukee, WI
- 9. Division of Pediatric Cardiology, Ann & Robert Lurie Children's Hospital of Chicago,
- 23 Northwestern University Feinberg School of Medicine, Chicago, IL
- 24 10. Pediatrics and Clinical and Translational Science, University of Pittsburgh,
- 25 Pittsburgh, PA
- 26 11. Vanderbilt University Medical Center, Division of Pediatric Cardiology, Nashville, TN
- 27 12. Children's Healthcare of Atlanta, Emory University, Atlanta, GA
- 13. Department of Pediatrics, The Heart Institute, Cincinnati Children's Hospital Medical
- 29 Center, University of Cincinnati College of Medicine, Cincinnati, OH
- 30 14. Division of Pediatric Cardiology, Children's Hospital of Colorado, University of
- 31 Colorado Anschutz Medical Campus
- 32 15. Washington University School of Medicine, Division of Pediatric Cardiology
- 16. Division of Pediatric Cardiology, Columbia University Vagelos College of Physicians
- 34 & Surgeons, New York, NY
- 17. Division of Cardiology & Cardiovascular Medicine, Children's Institute Department of
- 36 Heart Vascular & Thoracic, Cleveland, Ohio
- 18. Stollery Children's Hospital, Department of Pediatrics, University of Alberta,
- 38 Edmonton, AB
- 19. Division of Advanced Cardiac Therapies, Boston Children's Hospital
- 40

It is made available under a CC-BY-NC-ND 4.0 International license .

41 Short Title: The impact of Fontan circulatory failure on heart transplant

- 43 Corresponding Author: Kurt Schumacher.
- 44 <u>kurts@med.umich.edu</u>
- 45 1540 E Hospital Dr.
- 46 C.S. Mott Children's Hospital, Congenital Heart Center
- 47 Ann Arbor, MI 48109
- 49 Total Word Count: 5500

- ---

- -

66 <u>Abstract</u>

- **Background**: Fontan circulatory failure (FCF) is a chronic state in palliated single
- ventricle heart disease with high morbidity and mortality including heart failure,

It is made available under a CC-BY-NC-ND 4.0 International license .

multisystem end-organ disease, and need for heart transplant. Specific FCF morbidities
have not been rigorously defined, limiting study of how FCF morbidities impact pre- and
post-HT outcomes. We hypothesized that FCF-related morbidities affect survival from
heart transplant waitlisting through 1-year post-heart transplant.

73 Methods: This 20-center, retrospective cohort study collected demographic,

medical/surgical history, waitlist data, and peri- and post-heart transplant data, and *a priori* defined FCF-specific morbidities in Fontan patients who were listed for heart
transplant from 2008-2022. Univariate 2-group statistics compared surviving individuals
with those who 1) died anytime from waitlisting to 1-year post-heart transplant, 2) died

on the waitlist, 3) underwent transplant and died within 1-year post-transplant. Using

covariates from both univariate analyses, multivariable logistic regression determined

80 the primary study outcome of independent FCF risk factors for mortality between waitlist

81 and 1-year post-heart transplant

Results: Of 409 waitlisted patients, 24 (5.9%) died on the waitlist. Of the 341 (83.4%) 82 83 who underwent HT, 27 (8.5%) did not survive to 1-year. Univariate risk factors for 84 waitlist death included higher aortopulmonary collateral burden, > 1 hospitalization in prior year, younger age, sleep apnea, higher NYHA class, non-enrollment in school or 85 86 work, and single-parent home. Risk factors for 1-year post-heart transplant mortality 87 included hypoplastic left heart syndrome diagnosis, patent fenestration, anatomic 88 Fontan obstruction, clinical cyanosis (pulse oximetry < 90%), polycythemia, portal 89 variceal disease, mental health condition requiring treatment, and higher HLA class II 90 PRA. Of the patients not surviving from waitlisting to 1-year post-heart transplant,

It is made available under a CC-BY-NC-ND 4.0 International license .

91	independent risk factors for mortality included >1 hospitalization in the year prior to
92	waitlisting (adjusted odds ratio 2.0, p=0.05) and clinical cyanosis (adjusted odds ratio
93	5.0, p=0.002).
94	Conclusions: Patients with Fontan palliation selected for heart transplant have
95	significant mortality from waitlisting through transplant. Among FCF specific morbidities,
96	cyanosis is associated with worsened survival and necessitates further study. Clinical
97	morbidity of any type requiring repeated hospital admission also should prompt
98	consideration of heart transplant.
99	
100	
101	
102	
103	
104	
105	
106	
107	Clinical Perspective

108 What is new?

109	Survival through heart transplant in patients with Fontan physiology selected for
110	waitlisting has increased from previous reports, but this patient group still has
111	significant risk of mortality.
112	• Risk factors for waitlist mortality and post-transplant mortality are different.
113	Cyanosis and repeated hospitalizations prior to listing are independent risk
114	factors for mortality between waitlisting and 1-year post-heart transplant.
115	What are the clinical implications?
116	To successfully manage a patient through the entire transplant process, attention
117	to mitigating different risks in the waitlist and post-transplant phase is necessary.
118	Repeated hospitalization or significant cyanosis in a patient with Fontan
119	physiology should prompt consideration of heart transplant.
120	
121	
121	
122	
123	
124	
125	
126	Introduction
127	Fontan circulatory failure (FCF) is a multisystem syndrome directly resulting from the
128	physiologic ramifications of staged surgical palliation to total cavopulmonary

It is made available under a CC-BY-NC-ND 4.0 International license .

129 anastomosis, or the Fontan palliation, for single ventricle type congenital heart diseases 130 (CHD). Fontan palliation offers individuals born with single ventricle CHD long-term 131 survival with the alleviation of cyanosis, but it also results in lifelong venous 132 hypertension which may be accompanied by compromise in cardiac output and other 133 cardiovascular abnormalities. Since every organ is exposed to this abnormal circulation, 134 unique and Fontan-specific multisystem abnormalities have been described in the 135 recent era. These abnormalities do not occur in isolation, making FCF effectively a 136 systemic disease that is associated with poor long-term survival [1, 2]. 137 In an individual with Fontan circulation, heart transplant removes Fontan physiology and 138 restores normal biventricular circulation, thus it is used as a definitive therapy for FCF. 139 Unfortunately, individuals with FCF have reported post-heart transplant mortality that 140 exceeds that of most other types of heart disease [3, 4]. This is likely impacted by the 141 residual systemic implications of Fontan physiology as well as uncertainty surrounding 142 optimal timing for heart transplant evaluation referral in this lifelong chronic disease 143 state [5]. The differential survival between FCF and non-FCF patients is seen in the 144 early post-heart transplant period. For patients who survive the first-year, outcomes are 145 similar or superior to those with other heart diseases undergoing heart transplant ([4]. 146 The risk of mortality being most pronounced perioperatively and early post-HT suggests 147 that pre-operative FCF characteristics influence outcome. Attempts to study the FCF-148 transplant interaction have been limited by inadequate sample size or datasets with 149 marked lack of FCF-specific, granular data. A recent multicenter study in adults with 150 Fontan suggest FCF states may be important but did not fully characterize the unique.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 151 Fontan-specific multisystem effects of FCF [6]. As a result of these limitations, it
- 152 remains unclear which FCF disease states affect outcomes.
- 153 This retrospective study aimed to fully characterize patients with FCF who were
- 154 waitlisted for heart transplant by applying FCF-specific morbidity definitions, which were
- developed via Delphi methodology and previously described [7], to a large, multicenter
- 156 sample. It was hypothesized that FCF-specific morbidities would affect survival from
- 157 heart transplant waitlisting through 1-year post-heart transplant.

158 Methods

159 Study Design and Population

160 This is a retrospective cohort study of patients with Fontan-palliated single ventricle 161 CHD who underwent waitlisting for heart transplant between 2008 and 2022 at twenty congenital heart transplant centers in the United States and Canada. Both pediatric 162 patients and adults were eligible for inclusion. Multi-organ transplant patients were also 163 164 eligible for inclusion. Patients who were evaluated for transplant but never active on the 165 waitlist were not included as retrospective center capture of this population was variable 166 and incomplete. The study was approved by the Institutional Review Board at the 167 primary coordinating center at the University of Michigan as well as the Institutional 168 Review Boards of all 20 participating centers.

169 Data Extraction

De-identified patient-level data were extracted through medical chart review and
entered in HIPPA-compliant REDCap. Demographic data included sex, race, age,

It is made available under a CC-BY-NC-ND 4.0 International license .

172 congenital heart disease diagnosis, and surgical history. At time of waitlisting, extracted 173 data included NYHA class, history of hospitalizations in the year prior to waitlisting, multiple serum laboratories, and clinical testing data (e.g., echocardiogram, cardiac 174 175 MRI, cardiac catheterization, cardiopulmonary exercise testing, 6-minute walk testing 176 results). Data were also extracted on events that occurred during the waitlisting period 177 including initiation of new vasoactive treatments, invasive ventilation, new ventricular 178 assist device placement, support with extracorporeal membrane oxygenation, and 179 waitlist actions including removal from the waitlist and reason for removal. Mortality at 180 any point following listing and major post-transplant morbidities including rejection and infection in the first post-transplant year were also collected. 181 182 **Defining FCF-Specific Morbidities**

Previously described FCF morbidity definitions developed via modified Delphi methodology were applied to the extracted dataset [7]. Although the published definitions included graded severities for each morbidity, each morbidity was treated dichotomously as 'present' or 'absent' at the time of waitlisting for the purpose of this initial study due to the high number of variables in addition to FCF morbidities already being considered in the analysis.

189 Outcomes

The primary outcome was death at any time between waitlisting and 1-year post-heart transplant. Secondary outcomes included death prior to heart transplant (which included patients removed from the waitlist due to deterioration in clinical status) and death in a transplanted patient within 1-year post-transplant.

It is made available under a CC-BY-NC-ND 4.0 International license .

194 Statistical Analysis

195 Data are reported as frequency and percentage (%) for categorical variables and 196 median with interguartile range (IQR) or mean ± standard deviation (SD) for continuous 197 variables. Univariate associations of patient and clinical characteristics including a priori 198 defined FCF-specific morbidities with each of the study outcomes (waitlist death, death 199 within 1-year post-transplant, and death at any time between waitlisting and 1-year post-200 heart transplant) were examined using Chi-square test or Fisher's exact for categorical 201 variables and Wilcoxon rank-sum test or two-sample t-test for continuous variables. Due 202 to the limited number of cases of either waitlist mortality or 1-year post-transplant 203 mortality, multivariable analyses for those outcomes were not feasible. Specifically, 204 because of the study's a priori intent to define risk of both post-waitlist and post-205 transplant death as a single, unique outcome, multivariable logistic regression was used 206 to assess independent risk factors associated with mortality between waitlisting and 1-207 year post-transplant after excluding individuals still on the waitlist or de-listed from the 208 analysis. Factors found to be associated with mortality between waitlisting and 1-year 209 post-transplant in univariate analysis (p < 0.15) were further considered and included in 210 multivariable analyses. Due to the limited number of outcomes, the final model was 211 compiled after a series of prior models, each analyzing a limited number of covariates, 212 were explored to aid in variable selection and avoid overfitting. Multicollinearity among 213 candidate variables for multivariable analysis was examined using Variance Inflation 214 Factor. Adjusted odds ratios (aORs) with 95% confidence intervals from multivariable 215 logistic regression were reported. Kaplan-Meier curves were used to estimate survival 216 from waitlist to transplant, survival in the first-year post-transplant, and overall survival

It is made available under a CC-BY-NC-ND 4.0 International license .

- since waitlisting. All analyses were performed using SAS Version 9.4 (SAS Institute Inc.,
- 218 Cary, NC), with statistical significance set at a p-value < 0.05 using a two-sided test.
- 219 Authors KRS and MKC had full access to all data in the study and take responsibility for
- its integrity and the data analysis.

221 **Results**

- In total, 409 individuals with Fontan listed for heart transplant were included in the study
- 223 cohort. The cohort's demographic and prior surgical characteristics are presented in
- Table 1 as well as a consort diagram of the cohort (Figure 1)
- 225 Fontan patient characteristics at waitlisting and waitlist outcomes
- The median total follow-up time post-waitlisting for the cohort was 4.2 years (IQR 2-7.3).
- 227 Individual and testing characteristics at waitlisting are shown in Table 2. Additionally,
- cPRA data was available for 310 (75.8%) patients of the cohort; the majority did not
- exhibit serum anti-HLA antibodies but there was significant variation. The median total
- cPRA was 0% with IQR of 0-22% and a total range of 0-100%. The median class I
- cPRA was 0%, IQR 0-14%, total range 0-100%, and the median class II cPRA was 0%,
- 232 IQR 0-10%, range 0-100%.
- 233 FCF-related morbidity characteristics of the cohort are shown in Table 3. The variation in
- 234 FCF presentation within the cohort was broad. The median number of unique FCF-
- related morbidities present was 5 (IQR of 3-8 and a range of 0-15 morbidities),
- 236 demonstrating significant heterogeneity in FCF presentation and triggers for heart
- transplant evaluation and waitlisting.

It is made available under a CC-BY-NC-ND 4.0 International license .

238 Clinical status changed in a significant proportion of patients during the waitlisting 239 period. Vasoactive infusions were initiated in 247 (60.4%) of patients prior to heart transplant and continued until the time of heart transplant or death in 82.6% of those 240 241 patients. Mechanical ventilation was necessary in 57 (13.9%) patients after waitlisting 242 and continued until transplant or death in 45.6% of ventilated patients. A new ventricular 243 assist device was placed after waitlisting in 45 (11.0%) patients and remained in place in 91.1% of patients until transplant or death. Extracorporeal membrane oxygenation 244 245 was used in 20 (4.9%) patients and continued until death or transplant in 50.0% of those 246 patients.

Twenty-four (5.9%) patients died while waiting and 20 (4.9%) patients were removed
from the waitlist. Of those removed from the waitlist,4 were removed because they were
deemed to have too much morbidity/illness to remain a transplant candidate.

Additionally, 8 patients' status improved to no longer needing transplant at the time, and 8 patients' families requested to be removed from the waitlist or otherwise were unable to continue with transplant listing for reasons other than clinical status (these patients were censored from further analysis).

Figure 2 demonstrates the overall survival of waitlist patients. Notably, 24 (5.9%) patients remained on the waitlist for more than 1-year at the time of data collection. The following factors were associated with waitlist death in univariate analysis: higher grade (2+ or greater) of AP collaterals (28.6% vs. 15.3%, p=0.01), higher number of hospitalizations in the year preceding listing (hospitalization at the time of listing counted as 1 hospitalization; median 2 vs. 1, p=0.048), younger age at transplant evaluation (median 5.2 years vs. 13.1 years, p=0.003), sleep apnea (16.7% vs. 4.7%, p=0.04),

It is made available under a CC-BY-NC-ND 4.0 International license .

261 higher NYHA class (class IV; 41.7% vs. 23.2%, p=0.01), non-enrollment in school or 262 non-employment (45.8% vs. 17.9%, p=0.002), and single parent home at time of 263 evaluation (37.5% vs. 20.5%, p=0.04). 264 Post-heart transplant survival and transplant morbidities 265 In the 341 (83.4%) patients undergoing heart transplant, the median post-transplant 266 follow-up time was 4.2 years (IQR 1.9-7.2). Dual organ transplant occurred in 3.8% (N=13) of the cohort including 12 heart-liver transplants and 1 heart-kidney transplant; 267 268 due to the low number of patients undergoing dual-organ transplant they were included 269 in the overall cohort and not analyzed separately. A total of 27 (7.9%) patients died in 270 the first-year post-transplant. An additional 5 individuals (1.7%) died between 1 and 3-271 years post-transplant. Survival in the first-year post-transplant is demonstrated in 272 Figure 3. Those who died in the first post-transplant year were more likely to have a 273 diagnosis of hypoplastic left heart syndrome as the type of single ventricle CHD (81.5%) 274 vs. 61.9%, p=0.04), normal systolic function on echocardiogram (55.6% vs. 33.1%, 275 p=0.03), a patent fenestration (74.1% vs. 42.9%, p=0.002), a lower oxygen saturation 276 $(85.0 \pm 5.7 \text{ vs.} 88.9 \pm 6.3, p=0.003)$, a supplemental oxygen requirement (44.4% vs. 277 24.4%, p=0.02), a higher class II PRA (median 3% vs. 0%, p=0.03), Fontan pathway or 278 pulmonary artery obstruction (44.4% vs. 23.5%, p=0.02), clinical cyanosis defined as a 279 resting arterial oxygen saturation < 90% (88.9% vs. 56.4%, p=0.001), higher grade portal variceal disease (25.9% vs. 8.0%, p=0.01), polycythemia (25.9% vs. 9.7%, 280 p=0.02), and a mental health condition requiring treatment (51.9% vs. 28.0%, p=0.04). 281 282 In the first-year post-transplant, 38.9% of the cohort had allograft rejection requiring an 283 adjustment in immunosuppressive therapy; 27.5% had cellular-mediated rejection and

It is made available under a CC-BY-NC-ND 4.0 International license .

22.8% had antibody-mediated rejection (non-exclusive). Neither type of rejection, nor 284 285 rejection overall, was associated with 1-year mortality (25.9% in deaths vs 40.1% in survivors, p=0.14). Bacterial infection requiring parenteral antibiotics occurred in 22.2% 286 287 of the cohort in the first-year post-transplant; 37.0% of the patients that died had an 288 infection compared to 20.8% of survivors (p=0.06). Fungal infections were rarer but 289 occurred in 5.7% of the cohort including 18.5% of those who died vs 4.5% of survivors (p=0.01). Post-transplant bacterial infections were more likely to have occurred in those 290 291 who also had recurrent or severe bacterial infections prior to transplant (55.3% vs. 19.4%; p<0.0001). 292

293 Overall survival from time of waitlisting to 1-year post-heart transplant

For the primary outcome of survival from waitlist to 1-year post-transplant, 316 patients 294 295 met an outcome of either 1-year survival (n=289) or mortality (n=27). At the time of data 296 analysis, 24 were still on the waitlist at last follow-up, 25 were alive but had less than 1-297 year post-HT follow-up, and 20 were censored at the time of removal from the waitlist 298 for reasons other than clinical deterioration. Among the 15.0% (n=27) of individuals who 299 died, after seeindependent risk factors for mortality included >1 hospitalization in the 300 year prior to waitlisting (aOR 2.0, p=0.05) and clinical cyanosis (aOR 5.0, p=0.002) (Figure 4). Overall survival (including beyond 1-year post-transplant) since waitlisting 301 302 for the cohort is demonstrated in Figure 5.

303 Discussion

This study provides the largest, most comprehensive FCF-specific report of waitlist and
 post-heart transplant outcomes in individuals with Fontan physiology. Survival of

It is made available under a CC-BY-NC-ND 4.0 International license .

306 Fontan patients selected for transplant both on the waitlist and early post-transplant 307 among expert congenital heart centers was notably higher in this recent era cohort than previously seen which suggests significant gains in outcomes and improved 308 309 understanding of this population as a field. Compared to other multicenter reports of 310 transplant listing, waitlist mortality has improved to 5.9 % from previously reported 12-311 26%, and 1-year post transplant survival has improved to 92.1% from previously 312 reported 76%-89% [3, 4, 8, 9]. However, there remains significant mortality from the 313 time of waitlist to 1-year post-transplant that may still be improved upon, and unique risk 314 factors were determined via this study to help guide referral and treatment. 315 Risk factors for death on the waitlist and death post-transplant were remarkably 316 different. Patients who died while waiting were more likely to have worsened classical 317 symptoms of heart failure as evidenced by higher NYHA class. This may be exacerbated by worsened AP collateralization, also a risk factor, that can complicate 318 319 systemic cardiac output and oxygen delivery. They were also more likely to admitted to 320 the hospital repeatedly in the year prior to transplant, again likely driven by acute 321 symptoms. In contrast, those surviving the waiting period but dying early post-transplant 322 were more likely to have normal ventricular function by echo and less severe typical 323 heart failure symptoms but instead had other clinical findings that reflect the more 324 indolent and slowly progressive failure of the Fontan pathway and dysfunction from 325 chronically elevated central venous pressures. They were more likely to have Fontan 326 pathway obstruction, increased cyanosis, and portal varices. These findings suggest 327 chronic, lifetime changes that are not immediately reversed by transplantation impact 328 outcome even after restoration of biventricular physiology which is consistent with other

It is made available under a CC-BY-NC-ND 4.0 International license .

phenotypic characterizations of Fontan patients undergoing advanced therapies [10].
When waitlist and post-transplant risk factors are viewed together, they present a
complex picture for evaluation and monitoring in the Fontan patient. However, one can
conclude from this study, that acute new symptoms as well as progression of chronic
effects of Fontan circulation must both be continually assessed and when present,
referral to advanced heart failure teams should be considered.

335 While cyanosis has been invoked as an association with worsened outcomes in some 336 non-transplant-oriented studies [11, 12], its independent association with overall 337 mortality after listing for transplant in this study is novel and pronounced. While the only 338 other independent risk factor for mortality, multiple hospitalizations, may be a catch-all 339 for many severe forms of rarer FCF presentation, cyanosis is a single, easily 340 measurable clinical finding. It is not immediately clear why cyanosis is associated with 341 impaired survival. Cyanosis may be a marker of more deranged Fontan physiology. It 342 may be that chronic cyanosis causes systemic changes that lead to multiorgan disease 343 or predispose to perioperative morbidity such as bleeding. Potentially cyanosis also 344 leads to lifetime exercise impairment and deconditioning that affects ability to survive 345 the physical challenges of transplantation. Further, ongoing post-transplant cyanosis 346 may have direct effects on the graft. The causes that lead to cyanosis at time of 347 waitlisting being an independent risk factor warrants further study.

This study also serves as a detailed characterization FCF itself in a large cohort. In short, FCF and its clinical presentation are remarkably heterogeneous. The median number of unique FCF factors in the cohort was 5 with an IQR of 3 to 8 factors. This illustrates the challenges clinicians face in monitoring patients with Fontan physiology.

It is made available under a CC-BY-NC-ND 4.0 International license .

These individuals develop multiple clinical abnormalities all of which may change or worsen over time. How FCF morbidities should be tracked and what thresholds or combinations of factors should trigger transplant require additional study. In the future, we plan to study this cohort in detail to assess combinations of FCF morbidities and overall disease burden to look for presentation patterns that may help to guide surveillance testing, referral, and evaluation for advanced heart failure therapies. Finally, the impact of both psychosocial factors and social drivers of health must be

acknowledged. Both single parent household and non-enrollment in school or

360 employment were risk factors for waitlist mortality but neither were associated with posttransplant mortality. It is unclear whether this finding is related to the individual's degree 361 362 of heart failure or not. We fully recognize that these chart-based variables are not 363 comprehensive measures of social drivers of health, however, they may serve as an 364 indicator of possible inequities in access to care or historical marginalization. Similarly to 365 others who have discerned race-based and socio-economic disparities in waitlist 366 outcomes [13-15], these findings underscore the importance of prioritizing early 367 identification of and referral for heart failure therapy particularly among patients from 368 disadvantaged communities.

Notably, the presence of mental health condition(s) requiring treatment as indicated in the medical chart was found to negatively impact post-transplant survival. In fact, the risk of post-transplant mortality was almost doubled in those with mental health conditions requiring treatment. Given the higher rates of mental health diagnoses among the Fontan-palliated heart disease population [16-18] coupled with established associations between mental health comorbidity and post-transplant treatment It is made available under a CC-BY-NC-ND 4.0 International license .

adherence [19], regular surveillance and early referral for mental health care needs are
as important as physical FCF morbidity monitoring. While several FCF morbidities are
less modifiable to intervention, mental health represents a risk factor that can be
prevented or mitigated to improve post-transplant outcomes. Prevention-focused and
integrated psychosocial care is critical for the patient with Fontan-palliation and should
be prioritized at institutional and program levels to improve outcomes in this higher risk
group.

This study has several limitations. First, this is a retrospective cohort study and while 382 383 care was taken to collect data that could be obtained from chart review, many FCF 384 morbidities and other information may not be completely available from chart review. 385 Relatedly, some chart-based variables, such as single parent household and presence 386 of a mental health condition, do not fully capture the complexity of these constructs, 387 such as additional social drivers of health or type of mental health condition impacting 388 outcomes. Second, despite 20 centers and more than 400 patients, the overall mortality 389 was relatively low which compromises power to detect risk factors that may be still 390 important. Further, although 20 centers were included, they were chosen specifically as 391 centers with significant Fontan transplant volume and experience and the findings may 392 not be generalizable. Additionally, some findings, such as PRA, echocardiographic, and 393 angiographic findings may have site specific measures without real normalization of 394 values. There is also no information provided by this study regarding initial patient selection for waitlisting: data regarding patients who were declined for transplant is not 395 396 present and our understanding of this group remains very limited. Finally, other markers 397 of overall physical and mental health, such as physical frailty or psychological resilience

It is made available under a CC-BY-NC-ND 4.0 International license .

are commonly gauged as part of patient evaluation for advanced therapies. Those
indicators representing an individual's overall response to illness may be as or more
predictive than any individual morbidity.

These limitations inform the next phase in this critically important field of research given the growing number of Fontan transplants. The severity of individual FCF morbidities requires further study. Further, some patient factors, such as collateral vessels, may be modifiable, but whether modification affects outcome is unknown. Specific evaluation of frailty and resilience, both of which may be modified to improve outcomes in other disease states, is of significant interest.

407 **Conclusion**

408 Though improved compared to previous reports, Fontan-palliated patients selected for

409 transplant continue to have high mortality from waitlisting through transplant. Among

410 FCF specific morbidities, cyanosis is associated with worsened survival. The

411 presentation of FCF is very heterogeneous and warrants continued study to determine

412 specific Fontan patient surveillance and referral.

413

414 Acknowledgements:

Data collected by the Pediatric Cardiac Critical Care Consortium and Western Canadian
Single Ventricle Registry were used for this manuscript with permission from each
organization. The authors would also like to acknowledge the research staff at each
center that assisted in this effort.

It is made available under a CC-BY-NC-ND 4.0 International license .

419

420 Sources of funding:

- 421 This research was supported by a grant from the Additional Ventures and Enduring
- 422 Hearts organizations and a gift from the Van Hooser family.

423

424

425 REFERENCES

- 426 1. Allen, K.Y., et al., *Effect of Fontan-Associated Morbidities on Survival With Intact*
- 427 *Fontan Circulation.* Am J Cardiol, 2017. **119**(11): p. 1866-1871.
- 428 2. Goldberg, D.J., et al., *The failing Fontan: etiology, diagnosis and management.*
- 429 Expert Rev Cardiovasc Ther, 2011. **9**(6): p. 785-93.
- 430 3. Bernstein, D., et al., Outcome of listing for cardiac transplantation for failed
- 431 *Fontan: a multi-institutional study.* Circulation, 2006. **114**(4): p. 273-80.
- 432 4. Simpson, K.E., et al., Fontan Patient Survival After Pediatric Heart
- 433 Transplantation Has Improved in the Current Era. Ann Thorac Surg, 2017.
- 434 **103**(4): p. 1315-1320.
- 435 5. Chen, S., et al., Outcomes after initial heart failure consultation in Fontan
- 436 *patients.* Cardiol Young, 2024. **34**(5): p. 989-996.
- 437 6. Lewis, M.J., et al., *Clinical Outcomes of Adult Fontan-Associated Liver Disease*
- 438 and Combined Heart-Liver Transplantation. J Am Coll Cardiol, 2023. **81**(22): p.
- 439 2149-2160.

440	7.	Schumacher, K.R., et al., Achieving Consensus: Severity-Graded Definitions of
441		Fontan-Associated Complications to Characterize Fontan Circulatory Failure. J
442		Card Fail, 2024.
443	8.	Kovach, J.R., et al., Comparison of risk factors and outcomes for pediatric
444		patients listed for heart transplantation after bidirectional Glenn and after Fontan:
445		an analysis from the Pediatric Heart Transplant Study. J Heart Lung Transplant,
446		2012. 31 (2): p. 133-9.
447	9.	Kulshrestha, K., et al., The majority of pediatric Fontan patients have excellent
448		post-transplant survival. J Thorac Cardiovasc Surg, 2024. 167(6): p. 2193-2203.
449	10.	Dykes, J.C., et al., Clinical and hemodynamic characteristics of the pediatric
450		failing Fontan. J Heart Lung Transplant, 2021. 40 (12): p. 1529-1539.
451	11.	Schafstedde, M., et al., Persisting and reoccurring cyanosis after Fontan
452		operation is associated with increased late mortality. Eur J Cardiothorac Surg,
453		2021. 61 (1): p. 54-61.
454	12.	Egbe, A.C., et al., Predictors of procedural complications in adult Fontan patients
455		undergoing non-cardiac procedures. Heart, 2017. 103(22): p. 1813-1820.
456	13.	Bansal, N., et al., Impact of race and health coverage on listing and waitlist
457		mortality in pediatric cardiac transplantation. J Heart Lung Transplant, 2023.
458		42 (6): p. 754-764.
459	14.	Amdani, S., A. Tang, and J.D. Schold, Children from socioeconomically
460		disadvantaged communities present in more advanced heart failure at the time of
461		transplant listing. J Heart Lung Transplant, 2023. 42(2): p. 150-155.

462	15.	Singh, T.P., et al., Association of race and socioeconomic position with outcomes
463		in pediatric heart transplant recipients. Am J Transplant, 2010. 10(9): p. 2116-23.
464	16.	DeMaso, D.R., et al., Psychiatric Disorders in Adolescents With Single Ventricle
465		Congenital Heart Disease. Pediatrics, 2017. 139(3).
466	17.	McCormick, A.D., et al., Psychological functioning in paediatric patients with
467		single ventricle heart disease: a systematic review. Cardiol Young, 2022. 32(2): p.
468		173-184.
469	18.	Gonzalez, V.J., et al., Mental Health Disorders in Children With Congenital Heart
470		<i>Disease.</i> Pediatrics, 2021. 147 (2).
471	19.	Killian, M.O., et al., Psychosocial predictors of medication non-adherence in
472		pediatric organ transplantation: A systematic review. Pediatr Transplant, 2018.
473		22 (4): p. e13188.
474		
475		
476		
477		
478 479		
480		
481		
482		
	-	Table 1 Demographics and Surgical information (N-400)

Table 1. Demographics and Surgical Information (N=409)				
Male sex	253 (61.9)			
Race				
White/Caucasian	293 (71.6)			
Black/African American	61 (14.9)			

It is made available under a CC-BY-NC-ND 4.0 International license .

Asian	16 (3.9)
Native American	6 (1.5)
Native Pacific Islander	0 (0.0)
None of the above	27 (6.6)
Unknown	12 (2.9)
Ethnicity	
White Non-Hispanic	266 (65.0)
Black Non-Hispanic	59 (14.4)
Hispanic	49 (12.0)
Other	35 (8.6)
Primary cardiac diagnosis	
HLHS	254 (62.1)
Tricuspid Atresia	32 (7.8)
DILV	28 (6.8)
Unbalanced AVSD	38 (9.3)
PA/IVS	8 (2.0)
Other	49 (12.0)
Heterotaxy syndrome	52 (12.7)
Age at Fontan, years	3.1 (2.3-4.0)
Type of Fontan	, , , , , , , , , , , , , , , , , , ,
ECC	250 (61.1)
Lateral tunnel	141 (34.5)
Other	18 (4.4)
Fenestration used at Fontan	318 (77.8)
Fontan revision ever	51 (12.5)
Thoracic duct ligation ever	23 (5.6)
Pleurodesis ever	14 (3.4)
History of lymphatic intervention	18 (4.4)
Tracheostomy ever	9 (2.2)
Permanent pacemaker in place	116 (28.4)
* Data are presented as N (%) for categorical variat	bles and Median
(interquartile range) for continuous variable.	

483 484 485

Table 2. Transplant listing and Pre-transplant testing characteristics (N=409)			
Age at Listing, years	(N=407)	13.0 (6.5- 16.6)	
Time from Fontan to listing, years	(N=399)	9.2 (2.8-13.1)	
Status at listing			
1A		153 (37.4)	
1B		130 (31.8)	
2		77 (18.8)	
Adult listing		33 (8.1)	
Canadian listing		16 (3.9)	
NYHA class			
I		28 (6.8)	
I		119 (29.1)	
		143 (35.0)	
IV		90 (22.0)	
Unknown		29 (7.1)	
Insurance type at time of evaluation			
None	2 (0.5)		
Public		211 (51.6)	
Private		170 (41.6)	
Unknown		26 (6.4)	
Patient enrolled in school or employed at time	e of evaluation	307 (75.1)	
Single parent home at time of evaluation		91 (22.2)	
Parent/caregiver has a mental health history of (anxiety, mood, trauma, or substance use disc	74 (18.1)		
History of child protective service involvement	32 (7.8)		
Number of hospitalizations in the year prior to	transplant listing	1 (0-3)	
0		101 (24.7)	
1		105 (25.7)	
2-3		103 (25.2)	
4-5		43 (10.5)	
6+		11 (2.7)	
Unknown		46 (11.2)	
Weight-for-age z-score at time of evaluation < 20 years)	(N=360 for 2 < age	-1.0 ± 1.6	
Height-for-age z-score at time of evaluation < 20 years)	(N=359 for 2 < age	-1.5 ± 1.5	
BMI at time of evaluation, kg/m ²	(N=397 for age >	18.3 (16.2-	

2 years)		21.2)
O ₂ saturation at time of evaluation	, % (N=384)	88.4 ± 6.1
Supplemental oxygen at time of ex	aluation	98 (24.1)
Cardiac MRI findings		N=94 (23.1%)
Systemic ventricular function		
Normal		28 (29.8)
Mildly or Mild-Mo	derately depressed	18 (19.1)
Moderately or Mo	oderate-Severely depressed	22 (23.4)
Severely depress	sed	25 (26.6)
Missing/Not repo	rted	1 (1.1)
Ejection Fraction, %	(N=84)	38.8 ± 14.4
Atrioventricular valve regurgitation		
None		20 (21.3)
Mild or Mild-Mod	erate	28 (29.8)
Moderate or Moderate	lerate-Severe	28 (29.8)
Severe		16 (17.0)
Missing/Not repo	rted	2 (2.1)
Fenestration present	51 (54.3)	
Cardio-pulmonary exercise testi	ng	N=83 (20.4%)
O ₂ saturation at resting baseline, %	ю́ (N=69)	88.9 ± 5.5
Max VO ₂ , mL/kg/min	(N=72)	22.4 ± 9.9
VO ₂ at AT, mL/kg/min	(N=38)	20.8 ± 15.0
Ve/VCO ₂		108+71
(N=44)		40.0 ± 7.4
RER	(N=41)	1.1 ± 0.13
6-minute walk test		N=65 (16.0%)
Distances walked, meters		375 (263-459)
(N=63)		575 (200 400)
Lowest reported oxygen saturation	ı, % (N=61)	84.6 ± 8.3
Cardiac catheterization data	N=362 (88.9%)	
Ventricular End diastolic pressure, (N=318)	mmHg	10 (8-14)
Fontan pressure, mmHg (N=339)		16 (14-19)

It is made available under a CC-BY-NC-ND 4.0 International license .

Pulmonary vascular resistance, Woods-Units x m ²	20(13-27)
(N=315)	2.0 (1.3-2.7)
Qp indexed, L/min/m ²	25 ± 0.06
(N=314)	2.5 ± 0.90
Qs indexed, L/min/m ²	20 ± 11
(N=329)	5.0 ± 1.1
* Deterning and ended an NI (0() for eaterning ly and black and Marking	. <u>('a ta nav a nt'l a</u>

Data are presented as N (%) for categorical variables and Median (interquartile range) or Mean ± Standard deviation for continuous variables.

-			
486			
487			
488			
489			
490			
491			
492			

Table 3. FCF-specific morbidities	Not present	Present	Unknow
	Not present	i lesent	n
Fontan Function			
Anatomic Fontan pathway or pulmonary artery	299 (70 4)	113	Q (2 0)
obstruction	200 (70.4)	(27.6)	8 (2.0)
	162 (20.0)	240	6 (1 5)
	165 (59.9)	(58.7)	0(1.5)
Systemic venous abnormalities as a result of	282 (68 0)	60 (14 7)	67 (16 4)
venous insufficiency	202 (00.9)	00 (14.7)	07 (10.4)
Arrhythmia			
Atrial arrhythmia	200 (70 0)	108	11 (2 7)
Allal alliyullia	290 (70.9)	(26.4)	11(2.7)
Ventricular arrhythmia	329 (80.4)	70 (17.1)	10 (2.4)
Bradycardia	325 (79.5)	71 (17.4)	13 (3.2)

It is made available under a CC-BY-NC-ND 4.0 International license .

Chronic fluid overload states and lymphatic diseases

Chronic pleural effusions	296 (72.4)	107 (26.2)	6 (1.5)
Chronic ascites	256 (62.6)	149 (36.4)	4 (1.0)
Protein Losing Enteropathy	262 (64.1)	139 (34.0)	8 (2.0)
Plastic Bronchitis	371 (90.7)	31 (7.6)	7 (1.7)
Disorders of the airway and respiratory system			
Hemoptysis/Bronchopulmonary hemorrhage	382 (93.4)	13 (3.2)	14 (3.4)
Sleep apnea	300 (73.3)	27 (6.6)	82 (20.0)
Disorders of the liver and GI tract			
Fontan-Associated Liver Disease (FALD)	180 (44.0)	197 (48.2)	32 (7.8)
Portal/Hepatic Variceal Disease	286 (69.9)	50 (12.2)	73 (17.8)
Disorders of the Kidney			
Acute Kidney Injury in last 12 months	311 (76.0)	87 (21.3)	11 (2.7)
Disorders of the Blood			
Polycythemia	347 (84.8)	44 (10.7)	18 (4.4)
Thrombotic disease	317 (77.5)	68 (16.6)	24 (5.9)
Disorders of the Immune System			
Recurrent or severe bacterial infection	354 (86.6)	44 (10.8)	11 (2.7)
Disorders of the Musculoskeletal System			
Osteopenia/Osteoporosis	159 (38.9)	34 (8.3)	216 (52.8)
Disorders of the Skin			
Skin Atrophy	292 (71.4)	30 (7.3)	87 (21.3)
Disorders of the Endocrine System			
Adrenal insufficiency	330 (80.7)	30 (7.3)	49 (12.0)

History of stroke	328 (80.2)	67 (16.4)	14 (3
Psychiatric (Mood/Behavior)			
Mental health disorders	236 (57.7)	130 (31.8)	43 (1
Neurodevelopment			
Neurodevelopmental disorders	243 (59.4)	122 (29.8)	44 (1
* Data are presented as N (%)		(20.0)	
-igure 1. CONSORT diagram for the cohort.			
409 listed between 20	for HTx 08-2022		
		24 Still on th 20 Removed	ne waitlis from w
341 (83.4%) Received HTx	24 (Waith	5.9%) ist death	
↓ ↓ 27 (7.9%) 289 (84.8%)	25 (7.3%)		
Died within 1-year Survived to 1-year Sur	rvived Post-HTx		

504	
505	
506	
507	
508	
509	
510	
511	
512	
513	
514	
515	
516	
517	
518	
519	
520	
521 522 523	Figure 2. Waitlist survival censored at time of transplant or removal from the transplant waitlist for reasons other than being too ill for transplant candidacy. * Two patients with unknown date of listing were not included.
524	





545 survival from transplant to 1-year post-operative with factors affecting survival from 546 waitlisting until 1-year post-transplant.

It is made available under a CC-BY-NC-ND 4.0 International license .

It is made available under a CC-BY-NC-ND 4.0 International license .

547



565 were not included.

It is made available under a CC-BY-NC-ND 4.0 International license .



